Ashraf Z Badros
Overview
Explore the profile of Ashraf Z Badros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleckner A, Clingan C, Youngblood S, Kleckner I, Quick L, Elrod R, et al.
Res Sq
. 2025 Jan;
PMID: 39764090
Purpose: Time-restricted eating (TRE) helps regulate rest-activity rhythms, blood glucose, and other diurnally regulated energetics processes, which may have implications for persistent fatigue. In a randomized controlled trial, we tested...
2.
Badros A, Badros A, Foster L, Anderson Jr L, Chaulagain C, Pettijohn E, et al.
Blood
. 2024 Sep;
145(3):300-310.
PMID: 39331724
No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study...
3.
Li A, Kamangar F, Holtzman N, Rapoport A, Kocoglu M, Atanackovic D, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893268
Circulating plasma cells (CPCs) are detected in most multiple myeloma (MM) patients, both at diagnosis and on relapse. A small subset, plasma cell leukemia (PCL), represents a different biology and...
4.
Bhutani M, Blue B, Cole C, Badros A, Usmani S, Nooka A, et al.
Blood Cancer J
. 2023 Dec;
13(1):189.
PMID: 38110338
There are significant disparities with regards to incidence, timely diagnosis, access to treatment, clinical trial participation and health care utilization that negatively impact outcomes for African American patients with multiple...
5.
Peres L, Oswald L, Dillard C, De Avila G, Nishihori T, Blue B, et al.
Blood Adv
. 2023 Oct;
8(1):251-259.
PMID: 37855718
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of...
6.
Dimopoulos M, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison S, et al.
Lancet Oncol
. 2023 Jul;
24(7):e293-e311.
PMID: 37414019
Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022....
7.
Sklavenitis-Pistofidis R, Aranha M, Redd R, Baginska J, Haradhvala N, Hallisey M, et al.
Cancer Cell
. 2022 Nov;
40(11):1358-1373.e8.
PMID: 36379208
Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes. We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients...
8.
Kallen M, Koka R, Singh Z, Ning Y, Kocoglu M, Badros A, et al.
Leuk Res Rep
. 2022 Nov;
18:100358.
PMID: 36353199
New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for...
9.
Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson P, et al.
Lancet Haematol
. 2022 Oct;
9(11):e822-e832.
PMID: 36209764
Background: Iberdomide is a novel cereblon E3 ligase modulator with enhanced tumouricidal and immune-stimulatory effects compared with immunomodulatory drugs. In preclinical myeloma models, iberdomide has shown synergy with dexamethasone, proteasome...
10.
Rybinski B, Rapoport A, Badros A, Hardy N, Kocoglu M
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):e716-e729.
PMID: 35504807
Introduction: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous...